Denali Therapeutics (DNLI) Debt/EBITDA US GAAP (year values) |
|||||||||
2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
Debt/EBITDA | 1.69 | -22.4 | 2.81 | 3.86 | 5.46 | 1.58 | |||
Changes by years, y/y, % | -83% | -1 427% | -113% | +37% | +41% | -11.4% |
Denali Therapeutics. Debt/EBITDA
Denali Therapeutics. Debt/EBITDA, changes, %
Denali Therapeutics (DNLI) Debt/EBITDA US GAAP (quarter values) |
||||||||
2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
Debt/EBITDA | 6.47 | 5.11 | 4.40 | 1.74 | 1.58 | 1.58 | ||
Changes by years, y/y, % | +88% | +32% | +38% | -76% | -76% | |||
Changes by quarters, q/q, % | -11% | -21% | -14% | -60% | -9% |